Improving Drug Supply Chain Security

The authors discuss the FDA’s progress towards requiring pharmaceutical supply chain actors to develop an interoperable system for tracking and exchanging prescription drugs. In light of recent manufacturing issues related to cancer drugs and diabetes therapies, they recommend regulators impose stronger, more centralized interoperability standards and communicate clearer, more detailed guidance to stakeholders.